IP Library Patent Application 18017167
Patent Application
App. No. 18/017,167

ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/017,167
Abstract

Aspects of the disclosure relate to antibodies that bind to transferrin receptor (e.g., transferrin receptor 1) and complexes comprising the antibody covalently linked to a molecular payload. Methods of using the antibodies are also provided.

Claims (28)

1 . An antibody that binds to human transferrin receptor (TfR), wherein the antibody comprises:

a heavy chain variable region (VH) comprising an amino acid sequence at least 95% identical to SEQ ID NO: 77; and/or a light chain variable region (VL) comprising an amino acid sequence at least 95% identical to SEQ ID NO: 78.

2 . The antibody of claim 1 , wherein the antibody comprises:

a VH comprising an amino acid sequence of SEQ ID NO: 77 and a VL comprising an amino acid sequence of SEQ ID NO: 78.

3 . The antibody of claim 1 , wherein the antibody is selected from the group consisting of a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, an scFv, an Fv, and a full-length IgG.

4 . The antibody of claim 3 , wherein the antibody is a Fab fragment.

5 . The antibody of claim 4 , wherein the antibody comprises:

a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 93.

6 . The antibody of claim 5 , wherein the antibody comprises:

a heavy chain comprising the amino acid sequence of SEQ ID NO: 102 and a light chain comprising the amino acid sequence of SEQ ID NO: 93.

7 . The antibody of claim 1 , wherein the equilibrium dissociation constant (K D ) of binding of the antibody to the transferrin receptor is in a range from 10 −11 M to 10 −6 M.

8 . The antibody of claim 1 , wherein the antibody does not specifically bind to the transferrin binding site of the transferrin receptor and/or wherein the antibody does not inhibit binding of transferrin to the transferrin receptor.

9 . The antibody of claim 1 , wherein the antibody is cross-reactive with extracellular epitopes of two or more of a human, non-human primate and rodent transferrin receptor.

10 . A complex comprising the antibody of claim 1 covalently linked to a molecular payload.

11 . The complex of claim 10 , wherein the molecular payload is a diagnostic agent or a therapeutic agent.

12 . The complex of claim 10 , wherein the molecular payload is an oligonucleotide, a polypeptide, or a small molecule.

13 . The complex of claim 10 , wherein the antibody and the molecular payload are linked via a linker.

14 . The complex of claim 13 , wherein the linker is a cleavable linker.

15 . The complex of claim 13 , wherein the linker comprises a valine-citrulline sequence.

16 . A composition comprising the antibody of claim 1 .

17 . (canceled)

18 . A method of delivering a molecular payload to a cell, comprising contacting the cell with the complex of claim 10 .

19 .- 22 . (canceled)

23 . A method of delivering a molecular payload to the muscle of a subject, comprising administering to the subject an effective amount of the complex of claim 10 .

24 . (canceled)

25 . A method of treating a disease, comprising administering to a subject an effective amount of the complex of claim 10 , wherein the molecular payload is a therapeutic agent.

26 . The method of claim 25 , wherein the disease is a muscle disease and the molecular payload is a drug for treating the muscle disease.

27 . (canceled)

Assignments (2)
SECURITY INTEREST Recorded Jun 27, 2025
From: DYNE THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 071777/0300 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2023
From: SUBRAMANIAN, ROMESH R.; QATANANI, MOHAMMED T; WEEDEN, TIMOTHY; DESJARDINS, CODY A; QUINN, BRENDAN; NAJIM, JOHN
To: DYNE THERAPEUTICS, INC.
Reel/Frame 062478/0290 →